Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 November 6, 2024 Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences October 31, 2024 Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates October 30, 2024 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® October 21, 2024 Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis October 18, 2024 Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 October 2, 2024 Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference October 1, 2024 Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development September 30, 2024 Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) August 26, 2024 Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 7, 2024 Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates Pagination Current page 1 Page 2 Page 3 Page 4 Next page
Madrigal press releases are available below. Search them by keyword or browse by date. Year None202420232022202120202019201820172016 November 6, 2024 Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences October 31, 2024 Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates October 30, 2024 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® October 21, 2024 Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis October 18, 2024 Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 October 2, 2024 Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference October 1, 2024 Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development September 30, 2024 Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) August 26, 2024 Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference August 7, 2024 Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates Pagination Current page 1 Page 2 Page 3 Page 4 Next page
November 6, 2024 Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
October 31, 2024 Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates
October 30, 2024 Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
October 21, 2024 Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
October 18, 2024 Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
October 2, 2024 Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
October 1, 2024 Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
September 30, 2024 Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
August 26, 2024 Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 7, 2024 Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
